HFA
TXMD icon

Hoover Financial Advisors’s TherapeuticsMD TXMD Stock Holding History

Hoover Financial Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10
Closed -$1K – 455
2020
Q2 		$1K Buy
+10
New +$582 ﹤0.01% 483

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Hoover Financial Advisors's TXMD Position: Q3 2020 in Review

Hoover Financial Advisors sold out of TherapeuticsMD (TXMD) in Q3 2020, closing a stake of 10 shares — an estimated $1K sold.

Hoover Financial Advisors first reported a position in TXMD in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 142 funds tracked by Wall St. Rank hold TXMD as of Q3 2020.

  • Hoover Financial Advisors reported no remaining TherapeuticsMD position as of Q3 2020 after selling out during the quarter.
  • Hoover Financial Advisors sold 10 TherapeuticsMD shares in Q3 2020, an estimated $1K.
  • Hoover Financial Advisors first reported a position in TherapeuticsMD in Q2 2020 and held it in 1 quarter.
  • Hoover Financial Advisors's TherapeuticsMD position peaked at $1K in Q2 2020.
  • 142 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2020.

Based on Hoover Financial Advisors's 13F filing for Q3 2020, filed 21 Oct 2020.